Bristol-Myers Squibb (1BMY) Stock Forecast & Price Target

Compare

5 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

1BMY Analyst Ratings

Moderate Buy

8 Buy

11 Hold

1 Sell

Based on 20 analysts giving stock ratings to

Bristol-Myers

Squibb

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

1BMY Stock 12 Month Forecast

Average Price Target

€45.89

▼(-0.58% Downside)

Based on 20 Wall Street analysts offering 12 month price targets for Bristol-Myers Squibb in the last 3 months. The average price target is €45.89 with a high forecast of €57.86 and a low forecast of €31.48. The average price target represents a -0.58% change from the last price of €46.16.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"30":"€30","37":"€37","44":"€44","51":"€51","58":"€58"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":57.86254096,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€57.86</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":45.8901004996,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€45.89</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":31.48402964,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€31.48</span>\n  </div></div>","useHTML":true}}],"tickPositions":[30,37,44,51,58],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,42.35,43.543272381538465,44.73654476307692,45.929817144615384,47.12308952615385,48.31636190769231,49.50963428923077,50.70290667076923,51.89617905230769,53.08945143384615,54.282723815384614,55.47599619692308,56.66926857846153,{"y":57.86254096,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,42.35,42.62231542304615,42.89463084609231,43.166946269138464,43.439261692184616,43.711577115230774,43.983892538276926,44.25620796132308,44.52852338436923,44.80083880741539,45.07315423046154,45.34546965350769,45.61778507655385,{"y":45.8901004996,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,42.35,41.51415612615385,40.67831225230769,39.84246837846154,39.00662450461539,38.17078063076923,37.33493675692308,36.499092883076926,35.66324900923077,34.827405135384616,33.991561261538465,33.155717387692306,32.319873513846154,{"y":31.48402964,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":53.929,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.589,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.071,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.328,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.856,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 42, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.798,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.254,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 50, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.637,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 40, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.443,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 42, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.851,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 36, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.9,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.98,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 34, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.35,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 36, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€57.86

Average Price Target€45.89

Lowest Price Target€31.48

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Jason Gerberry

Bank of America Securities

€44.25→€51.91

Buy

12.45%

Upside

Upgraded

12/15/25

Bristol Myers upgraded to Buy from Neutral at BofABristol Myers upgraded to Buy from Neutral at BofA

Asad Haider

Goldman Sachs

€43.4→€48.5

Hold

5.07%

Upside

Reiterated

12/15/25

Bristol Myers price target raised to $57 from $51 at Goldman SachsBristol Myers price target raised to $57 from $51 at Goldman Sachs

Seamus Fernandez

Guggenheim

€52.76

Buy

14.29%

Upside

Upgraded

12/12/25

Bristol Myers upgraded to Buy from Neutral at GuggenheimBristol Myers upgraded to Buy from Neutral at Guggenheim

Srikripa Devarakonda

Truist Financial

―

Buy

―

Reiterated

12/12/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Bristol-Myers Squibb (NYSE: BMY), Immunovant (NASDAQ: IMVT) and Harmony Biosciences Holdings (NASDAQ: HRMY)

Terence Flynn

Morgan Stanley

€30.63→€31.48

Sell

-31.79%

Downside

Reiterated

12/12/25

Morgan Stanley Keeps Their Sell Rating on Bristol-Myers Squibb (BMY)

Matt Phipps

William Blair

―

Hold

―

Reiterated

12/11/25

Cautious Hold Rating on Bristol-Myers Squibb Amid Competitive Pressures in Hematology

Mohit Bansal

Wells Fargo

€45.1→€46.8

Hold

1.39%

Upside

Reiterated

12/10/25

Bristol-Myers Squibb (BMY) Receives a Hold from Wells Fargo

Rajesh Kumar

HSBC

€42.55→€45.1

Hold

-2.30%

Downside

Reiterated

12/10/25

Bristol Myers price target raised to $53 from $50 at HSBCBristol Myers price target raised to $53 from $50 at HSBC

Louise Chen

Scotiabank

€45.1

Hold

-2.30%

Downside

Reiterated

12/09/25

Bristol-Myers Squibb (BMY) Receives a Hold from Scotiabank

Unknown Analyst

Jefferies

Not Ranked

Jefferies

€57.86

Buy

25.35%

Upside

Reiterated

12/04/25

Bristol-Myers Squibb (BMY) Gets a Buy from Jefferies

David Risinger

Leerink Partners

―

Buy

―

Reiterated

12/03/25

Leerink views ADEPT-2 update as positive news, keeps Outperform on Bristol MyersLeerink views ADEPT-2 update as positive news, keeps Outperform on Bristol Myers

Geoff Meacham

Citi

€38.29

Hold

-17.05%

Downside

Reiterated

12/03/25

Analysts Offer Insights on Healthcare Companies: Masimo (NASDAQ: MASI), Bristol-Myers Squibb (NYSE: BMY) and Johnson & Johnson (NYSE: JNJ)

Chris Schott

J.P. Morgan

―

Buy

―

Reiterated

12/03/25

Bristol Myers ADEPT-2 update an 'incremental positive,' says JPMorganBristol Myers ADEPT-2 update an 'incremental positive,' says JPMorgan

Evan Seigerman

BMO Capital

€39.99

Hold

-13.36%

Downside

Assigned

12/02/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Bristol-Myers Squibb (NYSE: BMY) and Phreesia (NYSE: PHR)Amid delays in ADEPT-2 and enrollment adjustments, we revise our target price to $47.00 while maintaining a Market Perform rating.

Courtney Breen

Bernstein

―

Hold

―

Reiterated

11/26/25

Analysts Offer Insights on Healthcare Companies: ClearPoint Neuro (NASDAQ: CLPT) and Bristol-Myers Squibb (NYSE: BMY)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Jason Gerberry

Bank of America Securities

€44.25→€51.91

Buy

12.45%

Upside

Upgraded

12/15/25

Bristol Myers upgraded to Buy from Neutral at BofABristol Myers upgraded to Buy from Neutral at BofA

Asad Haider

Goldman Sachs

€43.4→€48.5

Hold

5.07%

Upside

Reiterated

12/15/25

Bristol Myers price target raised to $57 from $51 at Goldman SachsBristol Myers price target raised to $57 from $51 at Goldman Sachs

Seamus Fernandez

Guggenheim

€52.76

Buy

14.29%

Upside

Upgraded

12/12/25

Bristol Myers upgraded to Buy from Neutral at GuggenheimBristol Myers upgraded to Buy from Neutral at Guggenheim

Srikripa Devarakonda

Truist Financial

―

Buy

―

Reiterated

12/12/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Bristol-Myers Squibb (NYSE: BMY), Immunovant (NASDAQ: IMVT) and Harmony Biosciences Holdings (NASDAQ: HRMY)

Terence Flynn

Morgan Stanley

€30.63→€31.48

Sell

-31.79%

Downside

Reiterated

12/12/25

Morgan Stanley Keeps Their Sell Rating on Bristol-Myers Squibb (BMY)

Matt Phipps

William Blair

―

Hold

―

Reiterated

12/11/25

Cautious Hold Rating on Bristol-Myers Squibb Amid Competitive Pressures in Hematology

Mohit Bansal

Wells Fargo

€45.1→€46.8

Hold

1.39%

Upside

Reiterated

12/10/25

Bristol-Myers Squibb (BMY) Receives a Hold from Wells Fargo

Rajesh Kumar

HSBC

€42.55→€45.1

Hold

-2.30%

Downside

Reiterated

12/10/25

Bristol Myers price target raised to $53 from $50 at HSBCBristol Myers price target raised to $53 from $50 at HSBC

Louise Chen

Scotiabank

€45.1

Hold

-2.30%

Downside

Reiterated

12/09/25

Bristol-Myers Squibb (BMY) Receives a Hold from Scotiabank

Unknown Analyst

Jefferies

Not Ranked

Jefferies

€57.86

Buy

25.35%

Upside

Reiterated

12/04/25

Bristol-Myers Squibb (BMY) Gets a Buy from Jefferies

David Risinger

Leerink Partners

―

Buy

―

Reiterated

12/03/25

Leerink views ADEPT-2 update as positive news, keeps Outperform on Bristol MyersLeerink views ADEPT-2 update as positive news, keeps Outperform on Bristol Myers

Geoff Meacham

Citi

€38.29

Hold

-17.05%

Downside

Reiterated

12/03/25

Analysts Offer Insights on Healthcare Companies: Masimo (NASDAQ: MASI), Bristol-Myers Squibb (NYSE: BMY) and Johnson & Johnson (NYSE: JNJ)

Chris Schott

J.P. Morgan

―

Buy

―

Reiterated

12/03/25

Bristol Myers ADEPT-2 update an 'incremental positive,' says JPMorganBristol Myers ADEPT-2 update an 'incremental positive,' says JPMorgan

Evan Seigerman

BMO Capital

€39.99

Hold

-13.36%

Downside

Assigned

12/02/25

Courtney Breen

Bernstein

―

Hold

―

Reiterated

11/26/25

Analysts Offer Insights on Healthcare Companies: ClearPoint Neuro (NASDAQ: CLPT) and Bristol-Myers Squibb (NYSE: BMY)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Bristol-Myers Squibb

1 Month

xxx

Success Rate

11/20 ratings generated profit

Average Return

-1.27%

reiterated a xxx

rating 16 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 55.00% of your transactions generating a profit, with an average return of -1.27% per trade.

3 Months

xxx

Success Rate

21/33 ratings generated profit

Average Return

+1.71%

reiterated a xxx

rating 16 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 63.64% of your transactions generating a profit, with an average return of +1.71% per trade.

1 Year

David RisingerLeerink Partners

Success Rate

14/20 ratings generated profit

Average Return

+4.41%

reiterated a buy rating 16 days ago

Copying David Risinger's trades and holding each position for 1 Year would result in 70.00% of your transactions generating a profit, with an average return of +4.41% per trade.

2 Years

xxx

Success Rate

14/20 ratings generated profit

Average Return

+4.81%

reiterated a xxx

rating 16 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 70.00% of your transactions generating a profit, with an average return of +4.81% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

1BMY Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 1BMY has received 21 Buy Ratings, 36 Hold Ratings, and 4 Sell Ratings. 1BMY average Analyst price target in the past 3 months is 45.89.

Each month's total comprises the sum of three months' worth of ratings.

1BMY Financial Forecast

1BMY Earnings Forecast

Next quarter’s earnings estimate for 1BMY is €1.40 with a range of €1.18 to €1.90. The previous quarter’s EPS was €1.39. 1BMY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year 1BMY has Performed in-line its overall industry.

1BMY Sales Forecast

Next quarter’s sales forecast for 1BMY is €10.40B with a range of €10.11B to €10.67B. The previous quarter’s sales results were €10.41B. 1BMY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year 1BMY has Performed in-line its overall industry.

1BMY Stock Forecast FAQ

What is IT:1BMY’s average 12-month price target, according to analysts?

Based on analyst ratings, Bristol-Myers Squibb’s 12-month average price target is 45.89.

What is IT:1BMY’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for IT:1BMY, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Bristol-Myers Squibb a Buy, Sell or Hold?

Bristol-Myers Squibb has a consensus rating of Moderate Buy, which is based on 8 buy ratings, 11 hold ratings and 1 sell ratings.

What is Bristol-Myers Squibb’s share price target?

The average share price target for Bristol-Myers Squibb is 45.89. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €57.86 ,and the lowest forecast is €31.48. The average share price target represents -0.58% Decrease from the current price of €46.16.

What do analysts say about Bristol-Myers Squibb?

Bristol-Myers Squibb’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 20 Wall Streets Analysts.

How can I buy shares of Bristol-Myers Squibb?

To buy shares of IT:1BMY, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Bristol-Myers Squibb (1BMY) Stock Forecast & Price Target

1BMY Analyst Ratings

1BMY Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Bristol-Myers Squibb

1BMY Analyst Recommendation Trends

1BMY Financial Forecast

1BMY Earnings Forecast

1BMY Sales Forecast

1BMY Stock Forecast FAQ

Detailed List of Analyst Forecasts